top of page
1
First-in-human and proof-of-concept trials have successfully validated PlaqueTec’s LBS technology; trans-plaque signals revealed for numerous proteins
(West, N. E. J. et al. JACC:
Basic to Translational Science
2, 646-654, 2017)
2
Currently recruiting, BIOPATTERN will take a step further: endotyping a 300 patient CAD cohort, generating a unique data platform to inform the development of precision medicine in CAD
3
Subsequent planned trials will target additional specific clinical and ethnic phenotypes
The BIOPATTERN trial in 90 seconds
To find out more about our research or potential research collaborations, contact us
Trial Steering Committee
Chair
Dr Peter Libby
Cardiologist, Brigham and Womens Hospital, Boston, MA
Mallinckrodt Professor of Medicine, Harvard Medical School
President, International Atherosclerosis Society
Executive Editor, European Heart Journal
Chief Investigator
Dr Stephen Hoole
Consultant Interventional Cardiologist, Royal Papworth Hospital, Cambridge, UK
Affiliated Associate Professor, University of Cambridge
Dr Tom Johnson
Consultant Interventional Cardiologist, Bristol Heart Institute, UK
Associate Professor, University of Bristol
Prof Sheila Francis
Professor of Cardiovascular Biology, University of Sheffield, UK
Prof Adam Butterworth
Professor of Molecular Epidemiology, University of Cambridge, UK
The BIOPATTERN trial is advised by a renowned panel of clinical and scientific experts:
300 patients from across the UK with established CAD
LBS trans-plaque blood sampling
Extensive clinical and demographic data capture
OCT imaging
Genome-wide SNP array
Olink 3000+ protein analysis of samples
Wide-ranging additional exploratory analysis
BIOPATTERN:
Site of disease BIOmolecule capture and analysis in PATienTs with established coronary disease undERgoing iNtracoronary assessment.
bottom of page